Commentary/Editorials

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
Hussein A Tawbi, Ryan J Sullivan, David Feltquate, Theresa LaVallee, Naiyer A Rizvi, Elad Sharon, Jeffrey Sosman, Harriet M Kluger

Journal for ImmunoTherapy of Cancer Jul 2023, 11 (7) e007309; DOI: 10.1136/jitc-2023-007309
Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
Brian I Rini, James Brugarolas, Michael B Atkins

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e006361; DOI: 10.1136/jitc-2022-006361
In memoriam: Soldano Ferrone, MD, PhD (1940–2023)
Theresa Whiteside, Hassane M Zarour

Journal for ImmunoTherapy of Cancer Jan 2023, 11 (1) e006761; DOI: 10.1136/jitc-2023-006761
Liquid biopsies coming of age: biology, emerging technologies, and clinical translation- An introduction to the JITC expert opinion special review series on liquid biopsies
Mark D. Stewart, Valsamo Anagnostou

Journal for ImmunoTherapy of Cancer Jan 2023, 11 (1) e006367; DOI: 10.1136/jitc-2022-006367
Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications
Mario Sznol, Naiyer Rizvi

Journal for ImmunoTherapy of Cancer Jan 2023, 11 (1) e006346; DOI: 10.1136/jitc-2022-006346
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade
Ming Zheng

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005670; DOI: 10.1136/jitc-2022-005670
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
Eleonora Ghisoni, Matteo Morotti, Sara Colomer-Lahiguera, Manuela Eicher, George Coukos, Lionel Trueb, Massimo Di Maio

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e006082; DOI: 10.1136/jitc-2022-006082
Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer
Andrea Ardizzoni, Sergio Azevedo, Belen Rubio-Viqueira, Delvys Rodriguez-Abreu, Jorge Alatorre-Alexander, Hans J M Smit, Jinming Yu, Konstantinos Syrigos, Elen Höglander, Monika Kaul, Jonathan Tolson, Youyou Hu, Hans Kristian Vollan, Thomas Newsom-Davis

Journal for ImmunoTherapy of Cancer Nov 2022, 10 (11) e005581; DOI: 10.1136/jitc-2022-005581
Ensuring equity in the era of HLA-restricted cancer therapeutics
James W Smithy, Amanda Blouin, Lisa C Diamond, Michael Postow

Journal for ImmunoTherapy of Cancer Nov 2022, 10 (11) e005600; DOI: 10.1136/jitc-2022-005600
Gut microbiome-depleting antibiotic regimens are not tolerated by all mouse strains: learn from (our) bitter experience
Andrew A Almonte, George Cavic, Teresa Neeman, Anselm Enders, Aude M Fahrer

Journal for ImmunoTherapy of Cancer Nov 2022, 10 (11) e005575; DOI: 10.1136/jitc-2022-005575

Main menu

Commentary/Editorials

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Commentary/Editorials

Pages